Immucell (ICCC) EBITDA Margin (2010 - 2026)

Immucell (ICCC) has reported EBITDA Margin for 17 consecutive years, with 26.93% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin rose 1809.0% year-over-year to 26.93%; the trailing twelve-month figure through Jun 2026 stood at 9.22% (up 308.0% YoY), and the FY2025 full-year result was 5.97%, up 1216.0% from the prior year.
• EBITDA Margin improved to 26.93% in Q2 2026 per ICCC's latest filing, from 0.76% in the prior quarter.
• Across five years, EBITDA Margin topped out at 26.93% in Q2 2026 and bottomed at 65.46% in Q1 2023.
• Historically, EBITDA Margin has averaged 10.45% across 5 years, with a median of 6.85% in 2024.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 7497 bps in 2023, then surged 6132 bps in 2024.
• Over 5 years, EBITDA Margin stood at 41.77% in 2022, then jumped by 47 bps to 21.94% in 2023, then surged by 137 bps to 8.02% in 2024, then slumped by 109 bps to 0.76% in 2025, then surged by 3643 bps to 26.93% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 26.93%, 0.76%, and 0.36% for Q2 2026, Q4 2025, and Q3 2025 respectively.